Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Document › Details

Proteros Biostructures GmbH. (5/16/22). "Press Release: Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca". Munich.

Organisations Organisation Proteros Biostructures GmbH
  Group Proteros (Group)
  Organisation 2 AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
Products Product structure-based drug design
  Product 2 X-ray crystallography
Persons Person Neuefeind, Torsten (Proteros Biostructures 200610 Managing Director)
  Person 2 Verghese, Jacob (Trophic Communications 201811)

-- Under the expanded collaboration, Proteros will receive additional research funding, milestone payments plus royalties --

Proteros biostructures GmbH (“Proteros”), an expert in integrated structure-based drug discovery, announces today an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) focused on the discovery and development of novel epigenetic drugs. The new multi-year agreement builds on an ongoing collaboration with AstraZeneca announced in June 2021, to include the development of small molecule inhibitors targeting a second cancer-associated epigenetic protein.

Under the terms of this new agreement, Proteros will receive research funding and will be eligible for success-based research, development, and commercial milestone payments of up to USD 75 million plus tiered royalties on annual net sales. The collaboration combines Proteros’ expertise in the identification and characterization of inhibitors with novel binding mechanisms for technically challenging drug targets with AstraZeneca’s leadership in the discovery and development of oncology medicines.

“The expansion of our agreement with AstraZeneca with an additional drug discovery program reflects our successful ongoing collaboration to identify selective inhibitors for notoriously challenging disease targets,” said Dr. Torsten Neuefeind, CEO of Proteros. “This agreement strengthens our collaboration with a global biopharmaceutical leader and we look forward to joining forces again to discover novel inhibitors with the potential to effectively treat cancer patients in the future.”

The Proteros platform will ensure high selectivity to a specific target variant within and across multiple protein families through biochemical, biophysical and cellular assays supported by rapid turnaround in the structural determination of drug-target interactions by X-ray crystallography and cryo-Electron Microscopy technologies.

About Proteros biostructures GmbH

Proteros is a privately-held company with expertise in structure-based drug discovery powered by a cutting-edge discovery engine tailored to unlock even the most technically challenging disease-relevant targets. The company’s scientific rigor can accelerate overall research timelines for clients by solving challenges at the initial drug discovery and development stages. Proteros supports many of the top 20 world’s largest pharmaceutical companies and more than 250 pharmaceutical and biotech partners in the U.S., Europe and Japan.

For more information please visit

Contact Information

For Proteros

Dr. Torsten Neuefeind
Chief Executive Officer
Phone: +49 89 700761-0

Media Requests for Proteros

Trophic Communications
Jacob Verghese or Gretchen Schweitzer
Phone: +49 89 2070 89831

Record changed: 2023-06-05


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x200px

More documents for Proteros (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x300px

» top